The North America immunohematology market is projected to grow from USD 1.12 billion in 2025 to around USD 1.58 billion by 2035, expanding at a CAGR of 3.50%. Growth is driven by rising blood transfusion procedures, increasing chronic diseases, and advancements in diagnostic technologies.

North America Immunohematology Market Statical Scope

The growing prevalence of chronic diseases, rising surgical procedures, and expanding trauma care networks support the market growth. Hospitals and blood banks are adopting automated analyzers and molecular testing systems to improve workflow efficiency and reduce risk.

Investment in healthcare digitalization and standardized blood screening programs further strengthens the adoption across hospitals, diagnostic laboratories, and blood banks throughout the region.

North America Immunohematology Market Share, By Product, 2025 (%)

• Analyzers - Analyzers hold a significant portion, with a share of 38%, due to increasing laboratory automation. Hospitals and blood banks are adopting automated immunohematology analyzers for efficient and accurate blood screening to improve turnaround time and minimize manual errors.
• Reagents - Reagents dominate the segment, with a share of 62%, driven by their consistent demand for blood grouping, antibody screening and compatibility testing. The reagents are used in routine immunohematology testing procedures.

North America Immunohematology Market Share, By Technology, 2025 (%)

• Biochips - Biochips hold a smaller share, with a share of 10%, driven by increasing adoption of biochip technology by healthcare institutions to improve testing accuracy and support complex immunohematology applications in a technologically advanced diagnostic environment.
• Gel Cards - Gel Cards hold a significant portion, with a share of 22%, due to their reliability and strong compatibility with automated systems. Blood banks and laboratories are increasingly adopting gel cards in routine immunohematology testing as it improves testing consistency and reduce interpretation variability.
• Microplates - Microplates represent a steady segment, with a share of 14%, due to their cost-efficiency and suitability for high-throughput laboratory testing. Diagnostic laboratories and blood banks use microplate methods for large sample volumes, supporting routine immunology testing across healthcare networks.

North America Immunohematology Market Share, By End Use, 2025 (%)

• Hospitals - Hospitals lead the segment, with a share of 42%, driven by high surgical volumes, trauma care demand, and advanced transfusion services. Hospitals continue investing in automated blood testing systems to improve operational efficiency and support modern clinical workflow.
• Diagnostic Laboratories - Diagnostic Laboratories hold a significant portion, with a share of 33%, supported by rising demand for centralized testing and laboratory automation. Increasing testing volumes with a preference for accurate and fast diagnostics encourages laboratories to adopt advanced immunohematology systems.
• Blood Banks - Blood Banks account for a notable share, with a share of 25%, driven by the continuous need for blood screening, storage, and transfusion compatibility testing. Blood banks are increasingly implementing automated immunohematology systems to improve testing efficiency and maintain blood quality standards

Top Companies in the North America Immunohematology Market

• Grifols S.A.
• Immucor Inc.
• Thermo Fisher Scientific
• Merck KGaA
• Abbott Laboratories

Segments Covered in the Report

By Product

• Analyzers
• Reagents

By Technology

• Biochips
• Gel Cards
• Microplates
• PCR
• Erythrocyte-Magnetized Technology

By End-User

• Hospitals
• Diagnostic Laboratories
• Blood banks